Repligen’s third quarter was marked by revenue and non-GAAP profit that exceeded Wall Street expectations, driving a positive market reaction. Management attributed this performance to robust organic growth in proteins and chromatography segments, as well as continued strength in analytics and services. CEO Olivier Loeillot highlighted that the bioprocessing industry is recovering, with capital equipment order activity reaching a five-year high, despite muted revenue in that area. The addition of BioLife also contributed to Repligen’s diversified growth.
Is now the time to buy RGEN? Find out in our full research report (it’s free for active Edge members).
Repligen (RGEN) Q3 2026 highlights:
- Revenue $209.3 million vs S&P analysts’ estimates of $207 million (10.9% year-on-year growth, 1.1% beat)
- Adjusted EPS $0.53 vs S&P analysts’ estimates of $0.46 (14.5% beat)
- Adjusted EBITDA $43.84 million vs analyst estimates of $38.81 million (20.9% margin, 13% beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $848 million at the midpoint from $824 million, a 2.9% increase
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $2.07 at the midpoint
- Operating margin -14.1%, down from 8.9% in the same quarter last year
- Organic revenue rose 12.5% year on year (beat)
- Market capitalization $10.69 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Repligen’s Q3 earnings call
- Brendan Smith (TD Cowen) asked about the timing of BioLife integration benefits and the outlook for cell therapy growth; CEO Olivier Loeillot emphasized realized cost synergies and cautious growth assumptions, noting, “We have assumed…there could be no FDA approval of cell therapy for the first 2 years.”
- Matt Larew (William Blair) inquired about the drivers behind the weaker filtration results; Loeillot pointed to timing issues in filtration system deliveries, which pushed expected sales into 2027, but expressed confidence in a future rebound.
- Dan Arias (Stifel) questioned product mix implications for margins; CFO Jason Garland explained that while equipment has below-average margins, filtration and proteins are accretive, making overall mix impact neutral to slightly positive.
- Douglas Schenkel (UBS) probed the lag between rising equipment orders and revenue recognition; Loeillot confirmed that delayed customer decisions mean most revenue will be realized in 2027, despite a strong order pipeline.
- Puneet Souda (Leerink Partners) asked about on-shoring’s effect on orders; Loeillot acknowledged modest current impact but expects more substantial contributions as pharma customers allocate capital between regions.
Catalysts in upcoming quarters
In the coming quarters, our analysts will focus on (1) the pace of BioLife integration and realization of promised synergies, (2) whether capital equipment order momentum translates into revenue growth as industry investment picks up, and (3) the sustainability of strong analytics and protein segment performance. Developments in cell and gene therapy approvals and the progression of on-shoring initiatives will also be critical markers of execution.
Repligen currently trades at $173.85, down from $180.17 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
The best stocks for high-quality investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
